Brookstone Capital Management’s ImmunityBio IBRX Stock Holding History

Brookstone Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18,715	Closed	-$101K	–	978
2024 Q1	$101K	Buy	+18,715	New	+$84.7K	﹤0.01%	906

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brookstone Capital Management's IBRX Position: Q2 2024 in Review

Brookstone Capital Management sold out of ImmunityBio (IBRX) in Q2 2024, closing a stake of 18,715 shares — an estimated $101K sold.

Brookstone Capital Management first reported a position in IBRX in Q1 2024 and held it in 1 quarter. The position peaked at $101K in Q1 2024. 193 funds tracked by Wall St. Rank hold IBRX as of Q2 2024.

Brookstone Capital Management reported no remaining ImmunityBio position as of Q2 2024 after selling out during the quarter.
Brookstone Capital Management sold 18,715 ImmunityBio shares in Q2 2024, an estimated $101K.
Brookstone Capital Management first reported a position in ImmunityBio in Q1 2024 and held it in 1 quarter.
Brookstone Capital Management's ImmunityBio position peaked at $101K in Q1 2024.
193 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2024.

Based on Brookstone Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.